Table 5.
Antibiotic treatment and rates of microbiological and clinical failure versus mode of contamination and department in a series of 371 acute prostatitis (AP).
| 371 AP patients | ||||||||
| Total patients | Community acquired AP | Nosocomial AP | Community acquired Versus nosocomial AP | Urology | Infectious Diseases | Internal Medicine | Geriatrics | |
| n = 371 | n = 293 | n = 78 | p value | n = 178 | n = 115 | n = 48 | n = 30 | |
| Antibiotic treatment | ||||||||
| Empirical choice | ||||||||
| Bi-therapy | 215 (58%) | 172 (59%) | 43 (55%) | 0.7 | 123 (69%) | 63 (55%) | 20 (42%) | 9 (30%) |
| Use of fluoroquinolone | 234 (63%) | 187 (64%) | 47 (60%) | 0.7 | 148 (83%) | 47 (41%) | 20 (42%) | 19 (63%) |
| Use of 3rd generation cephalosporin | 113 (30%) | 85 (29%) | 28 (36%) | 0.3 | 25 (14%) | 59 (51%) | 22 (46%) | 7 (23%) |
| Use of amino glycosides | 195 (52%) | 165 (56%) | 30 (38%) | 0.007 | 120 (67%) | 60 (52%) | 14 (29%) | 1 (3%) |
| Use of other classes | 44 (12%) | 28 (10%) | 16 (21%) | 0.01 | 8 (4%) | 12 (10%) | 12 (25%) | 12 (40%) |
| Inadequate* | 42/269 (16%) | 17/210 (8%) | 25/59 (42%) | <0.001 | 27/137 (20%) | 4/76 (5%) | 6/31 (19%) | 5/25 (25%) |
| Adapted choice | ||||||||
| Bi-therapy | 15 (4%) | 13 (4%) | 2(3%) | 0.7 | 3 (2%) | 11 (10%) | 0 (0%) | 1 (3%) |
| Use of fluoroquinolone | 285 (77%) | 242 (82%) | 43 (55%) | <0.001 | 148 (83%) | 85 (74%) | 31 (65%) | 21 (70%) |
| Use of 3rd generation cephalosporin | 18 (5%) | 11 (4%) | 7 (9%) | 0.1 | 9 (5%) | 1 (1%) | 5 (10%) | 3 (10%) |
| Use of cotrimoxazole | 52 (14%) | 44 (15%) | 8 (10%) | <0.001 | 13 (7%) | 33 (29%) | 5 (10%) | 1 (3%) |
| Use of other classes | 31 (8%) | 9 (3%) | 22 (28%) | <0.001 | 11 (6%) | 7 (6%) | 7 (15%) | 6 (20%) |
| Inadequate* | 18/269 (7%) | 11/210 (5%) | 7/59 (12%) | 0.1 | 14/137 (10%) | 1/76 (1%) | 1/31 (3%) | 2/25 (8%) |
| Total duration (days) | 32 | 34 | 29 | 0.13 | 22 | 49 | 33 | 33 |
| Bacterial failure at follow-up | 37/153 (24%) | 23/124 (19%) | 14/29 (48%) | 0.002 | 16/76 (21%) | 2/32 (6%) | 1/6 (16%) | 4/9 (44%) |
| - same strain | 7 | 3 | 4 | 8 | 0 | 0 | 0 | |
| - other strain | 30 | 20 | 10 | 8 | 2 | 1 | 4 | |
| Clinical failure at follow-up | 137/183 (75%) | 98/135 (73%) | 39/48 (83%) | 0.3 | 88/123 (71%) | 28/36 (78%) | 8/10 (80%) | 13/14 (92%) |
* The adequacy of the treatment was studied for the 169 patients with a positive urine culture and an antibiotic-resistance pattern of the pathogenic strain.